Omeros
OMERAlgoritmens signaler
- ›Starkt 3m-momentum (+15.8%)
- ›Starkt 6m-momentum (+94.3%)
- ›Starkt 12m-momentum (+103.5%)
- ›Pris över MA50 och MA200 (uppåttrend)
- ›Hög volatilitet (59% årlig)
- ›+397% från 52v-botten
- ›Ökad handelsvolym (+61%)
📰 Senaste nyheter & analys
Källor: Placera, Nyhetsbyrån Direkt, Google NewsHere's Why Omeros (OMER) is a Great Momentum Stock to Buy - Yahoo Finance
1 d sedanHere's Why Omeros (OMER) is a Great Momentum Stock to Buy Yahoo Finance
Yahoo FinanceOMER Stock Price, Quote & Chart | OMEROS CORP (NASDAQ:OMER) - ChartMill
5 d sedanOMER Stock Price, Quote & Chart | OMEROS CORP (NASDAQ:OMER) ChartMill
ChartMillOMER News | OMEROS CORP (NASDAQ:OMER) - ChartMill
5 d sedanOMER News | OMEROS CORP (NASDAQ:OMER) ChartMill
ChartMillIngalls & Snyder (NASDAQ: OMER) holds 3.47M shares, 4.8% stake - Stock Titan
5 d sedanIngalls & Snyder (NASDAQ: OMER) holds 3.47M shares, 4.8% stake Stock Titan
Stock TitanDoes Omeros (OMER) Have the Potential to Rally 266.67% as Wall Street Analysts Expect? - qz.com
2026-04-10Does Omeros (OMER) Have the Potential to Rally 266.67% as Wall Street Analysts Expect? qz.com
qz.comOmeros (NASDAQ:OMER) Shares Down 6.5% - Here's Why - MarketBeat
2026-04-02Omeros (NASDAQ:OMER) Shares Down 6.5% - Here's Why MarketBeat
MarketBeatOmeros stock rises after Q4 earnings beat (OMER:NASDAQ) - Seeking Alpha
2026-04-01Omeros stock rises after Q4 earnings beat (OMER:NASDAQ) Seeking Alpha
Seeking AlphaOmeros (OMER): Revisiting Valuation After a Powerful Multi‑Year Share Price Repricing - Yahoo Finance
2025-12-25Omeros (OMER): Revisiting Valuation After a Powerful Multi‑Year Share Price Repricing Yahoo Finance
Yahoo FinanceOmeros Corporation Reports Third Quarter 2025 Financial Results
2025-11-13Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2025, which include: Net loss for the thir
OmerosBusinesswireOmeros Corporation to Announce Third Quarter Financial Results on November 13, 2025
2025-11-11Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2025, on Thursday, November 13, 2025, after the market closes.
OmerosBusinesswireOmeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group
2025-10-16Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing survival outcomes in adult
OmerosBusinesswireOmeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program
2025-09-02Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes in adult and pediatric patients with l
OmerosBusinesswireOmeros Corporation Reports Second Quarter 2025 Financial Results
2025-08-14Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2025, which include: Net loss for the second q
OmerosBusinesswireOmeros Corporation to Announce Second Quarter Financial Results on August 14, 2025
2025-08-11Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2025, on Thursday, August 14, 2025, after the market closes. Omeros
OmerosBusinesswireOmeros Corporation Announces Pricing of $22 Million Registered Direct Offering
2025-07-25Omeros Corporation (Nasdaq: OMER) (“Omeros” or the “Company”) announced that on July 24, 2025 it entered into a securities purchase agreement with Polar Asset Management Partners to sell approximately
OmerosBusinesswireOmeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA
2025-06-27Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab for the treatment of hemat
OmerosBusinesswire